Preparation of 131I-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected rats
Küçük Resim Yok
Tarih
2013
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
We aimed to assess the ability of 131I-Pyrimethamine scintigraphy to detect the lesions of Toxoplasma gondii infection. An experimental model of toxoplasmosis was developed. The presence of toxoplasmosis was confirmed 60 days after implantation. Pyrimethamine was radioiodinated with I-131. The radioligand was validated by the requisite quality control tests to check its radiolabeling efficiency, in vitro stability and radiochemical purity etc. 131I-Pyrimethamine (specific activity: 7.08 MBq/mol) was injected intravenously into the tail vein of the control and infected rats. Static whole body images of the rats were acquired under the gamma camera at 5min, 45min, 2h, 6h, and 24h following the intravenous administration of the radioactivity (3.7 MBq/rat). Then the scintigraphic data were analyzed both visually and semiquantitatively. Regions of interest (ROIs) were drawn over the organs (thyroid, stomach, liver, bladder, and soft tissues) to calculate the ratios of the radiotracer in infected vs. control rats. The mean ratio of radiotracer in infected/control rats in the liver and diaphragm was over 1 at 45min which persisted till 24h. In conclusion, 131I-Pyrimethamine may be useful agent for diagnosis toxoplasmosis especially involving liver and diaphragm, needs further preclinical validation before being extended for use in clinical applications. © 2013 Informa UK, Ltd.
Açıklama
Anahtar Kelimeler
131I-Pyrimethamine, Radionuclide imaging, Toxoplasma gondii, Toxoplasmosis, Wistar rat
Kaynak
Journal of Drug Targeting
WoS Q Değeri
Scopus Q Değeri
Q1
Cilt
21
Sayı
2
